Chemomab Therapeutics Ltd. (NASDAQ:CMMB – Get Rating) saw a significant decline in short interest during the month of March. As of March 31st, there was short interest totalling 16,800 shares, a decline of 32.5% from the March 15th total of 24,900 shares. Based on an average trading volume of 72,300 shares, the short-interest ratio is presently 0.2 days. Approximately 0.2% of the shares of the stock are short sold.
In other Chemomab Therapeutics news, Director Neil Harris Cohen bought 6,000 shares of the business’s stock in a transaction on Monday, March 14th. The stock was bought at an average price of $4.35 per share, for a total transaction of $26,100.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders have acquired 10,750 shares of company stock valued at $45,440. 12.22% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in CMMB. ARK Investment Management LLC grew its stake in Chemomab Therapeutics by 48.1% during the fourth quarter. ARK Investment Management LLC now owns 267,292 shares of the company’s stock worth $1,844,000 after buying an additional 86,769 shares during the period. Advisor Group Holdings Inc. purchased a new stake in Chemomab Therapeutics during the third quarter worth approximately $608,000. Virtu Financial LLC purchased a new stake in Chemomab Therapeutics during the fourth quarter worth approximately $155,000. Geode Capital Management LLC purchased a new stake in Chemomab Therapeutics during the third quarter worth approximately $152,000. Finally, GSA Capital Partners LLP purchased a new stake in Chemomab Therapeutics during the fourth quarter worth approximately $78,000. Institutional investors own 28.75% of the company’s stock.
Chemomab Therapeutics (NASDAQ:CMMB – Get Rating) last released its earnings results on Wednesday, March 9th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.04). As a group, analysts anticipate that Chemomab Therapeutics will post -1.94 EPS for the current fiscal year.
A number of equities analysts have recently weighed in on the stock. Zacks Investment Research lowered shares of Chemomab Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, March 14th. Oppenheimer lowered their target price on shares of Chemomab Therapeutics from $30.00 to $20.00 and set an “outperform” rating for the company in a report on Thursday, March 10th.
Chemomab Therapeutics Company Profile (Get Rating)
Chemomab Therapeutics Ltd. engages in the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 16, 2021. Chemomab Therapeutics Ltd.
- Get a free copy of the StockNews.com research report on Chemomab Therapeutics (CMMB)
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- UiPath Stock is Nearing Rock Bottom Down Here
- Array Technologies Stock Giving Another Ground Floor Entry
Receive News & Ratings for Chemomab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemomab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.